Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -28.69% is in line with its 5-year average of -29.80%, around the middle of its 5-year range (-63.87%–4.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 142.99% below its 12-month average of -11.81%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -28.69%.
RETURN ON INVESTED CAPITAL (ROIC)
-28.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-11.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-31.82%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-29.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-142.99%
CURRENT VS 3Y AVG
+9.83%
CURRENT VS 5Y AVG
+3.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+19.55%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$833.81M
Return on Invested Capital (ROIC)
-28.69%
TTM Avg
-11.81%
3Y Avg
-31.82%
5Y Avg
-29.80%
Market Cap
$838.16M
Return on Invested Capital (ROIC)
-31.17%
TTM Avg
-29.64%
3Y Avg
-85.48%
5Y Avg
-85.48%
Market Cap
$838.62M
Return on Invested Capital (ROIC)
-23.80%
TTM Avg
-58.06%
3Y Avg
-39.20%
5Y Avg
-32.57%
Market Cap
$828.48M
Return on Invested Capital (ROIC)
-26.54%
TTM Avg
-38.64%
3Y Avg
-38.64%
5Y Avg
-38.64%
Market Cap
$817.67M
Return on Invested Capital (ROIC)
-7.99%
TTM Avg
-8.85%
3Y Avg
-21.37%
5Y Avg
-42.56%
Market Cap
$816.13M
Return on Invested Capital (ROIC)
-37.39%
TTM Avg
-65.53%
3Y Avg
-61.64%
5Y Avg
-93.68%
Market Cap
$852.35M
Return on Invested Capital (ROIC)
-163.39%
TTM Avg
-91.89%
3Y Avg
-60.67%
5Y Avg
-60.67%
Market Cap
$853.13M
Return on Invested Capital (ROIC)
18.72%
TTM Avg
24.77%
3Y Avg
-14.92%
5Y Avg
-18.89%
Market Cap
$855.38M
Return on Invested Capital (ROIC)
-94.76%
TTM Avg
-114.06%
3Y Avg
-144.57%
5Y Avg
-144.57%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $833.81M | -28.69% | -11.81% | -31.82% | -29.80% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -31.17% | -29.64% | -85.48% | -85.48% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -23.80% | -58.06% | -39.20% | -32.57% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | -26.54% | -38.64% | -38.64% | -38.64% |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | -7.99% | -8.85% | -21.37% | -42.56% |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | -37.39% | -65.53% | -61.64% | -93.68% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -163.39% | -91.89% | -60.67% | -60.67% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 18.72% | 24.77% | -14.92% | -18.89% |
| Alumis Inc. (ALMS)vs › | $855.38M | -94.76% | -114.06% | -144.57% | -144.57% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -16.05% | -26.23% | -9.21% | 8.44% |
ROIC
-28.7%
ROE
-33.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -28.69% |
| 2026-03-31 | -22.28% |
| 2025-12-31 | -14.10% |
| 2025-09-30 | 2.04% |
| 2025-06-30 | 4.00% |
| 2025-03-31 | -0.41% |
| 2024-12-31 | -28.78% |
| 2024-09-30 | -47.17% |
| 2024-06-30 | -46.20% |
| 2024-03-31 | -63.87% |
| 2023-12-31 | -55.73% |
| 2023-09-30 | -61.41% |
| 2023-06-30 | -50.99% |
| 2023-03-31 | -42.40% |
| 2022-12-31 | -35.47% |
| 2022-09-30 | -30.76% |
| 2022-06-30 | -27.06% |
| 2022-03-31 | -25.69% |
| 2021-12-31 | -20.84% |
| 2021-09-30 | -16.54% |
| 2021-06-30 | -13.39% |
| 2021-03-31 | -20.54% |
| 2020-12-31 | -139.34% |
